• Phenothiazines Boost Macrophage Antibacterial Defense

  2026-09-05

  The 2025 reference study shows that phenothiazines strengthen macrophage control of intracellular bacteria by increasing lysosomal activity, autophagy, and reactive oxygen species accumulation. Its host-directed therapy framework supports mechanistic testing of phenothiazine compounds while emphasizing that immune-cell protection, rather than direct bacterial killing, is the central therapeutic concept.

• IRG1–Itaconic Acid Control of TBK1 Signaling

  2026-09-05

  Chai et al. identify an IRG1–itaconic acid feedback pathway that restrains TBK1-driven type I interferon production through alkylation of TBK1 at Cys605 and disruption of its dimerization. The study also introduces ITA-5 and ITA-9 as itaconic acid-based candidate inhibitors, offering a mechanistic framework for limiting excessive interferon signaling while highlighting important questions about specificity, context, and translational maturity.

• AP1903: Tuning FKBP Assays by Expression Level

  2026-09-04

  AP1903 is an FKBP-binding ligand for controlled protein activation, apoptosis pathway research, and conditional cell ablation. This article explains how pairing chemical dimerization with calibrated transgene expression can make FKBP assays more interpretable.

• Hydroxytyrosol: Mechanisms and Research Use

  2026-09-04

  Hydroxytyrosol is an olive-derived phenolic antioxidant bioactive compound studied for oxidative stress modulation, inflammatory signaling, and cardiovascular health research. Cellular evidence links hydroxytyrosol with lower reactive oxygen species and lipid peroxidation, anti-inflammatory macrophage changes, and increased cholesterol efflux, but these findings do not establish clinical treatment efficacy.

• Leucovorin Calcium in 3D Antifolate Assays

  2026-09-03

  Leucovorin Calcium, or calcium folinate, can turn methotrexate rescue from a simple viability endpoint into a mechanistic assay variable. This article explains how to use folate rescue logic in patient-derived gastric cancer assembloid workflows while accounting for stromal regulation and model-specific drug responses.

• SU5416: VEGFR2 Workflows for Angiogenesis Research

  2026-09-02

  SU5416 (Semaxanib) provides a focused way to dissect VEGFR2-dependent endothelial signaling, tumor vascularization, and angiogenic phenotypes. This workflow also incorporates normoxic HIF1α biology from recent vascular research, helping investigators distinguish receptor blockade from metabolism-driven background activation.

• Netarsudil (AR-13324) Experimental Workflow

  2026-09-02

  Netarsudil (AR-13324) combines selective ROCK pathway modulation with a practical opportunity for siRNA codelivery research. This workflow connects formulation screening, trabecular meshwork cell phenotyping, and troubleshooting while separating validated findings from translational hypotheses.

• Angiotensin 1/2 (1-6): RAS Research Guide

  2026-09-01

  Angiotensin 1/2 (1-6) is the Asp-Arg-Val-Tyr-Ile-His hexapeptide used to investigate angiotensin-fragment biology and renin-angiotensin system research. Product documentation defines its identity and handling properties, while a 2025 study reports that angiotensin (1-6) enhanced SARS-CoV-2 spike–AXL binding in an antibody-based assay, without establishing clinical antiviral activity.

• Escitalopram: From Transporter Assays to Clinical Insight

  2026-08-31

  Escitalopram research often stops at serotonin transporter selectivity. This article connects molecular assay interpretation with subgroup-aware clinical evidence, showing how Lexapro can support more rigorous antidepressant and anxiolytic activity studies.

• Filipin III for Cholesterol Membrane Workflows

  2026-08-31

  Filipin III supports practical cholesterol mapping in cells, membrane fractions, vesicles, and ultrastructural preparations. This workflow-focused guide connects cholesterol readouts with PHMG-induced macrophage foam-cell biology while emphasizing controls, signal interpretation, and solution stability.

• Valemetostat: From EZH2 Biology to Assay Design

  2026-08-30

  Valemetostat (DS-3201) is an EZH2-focused epigenetic cancer therapy with activity against clinically relevant EZH2 mutants. This article translates its mechanism and phase 1 evidence into practical assay-design decisions for lymphoma research.

• Collagen VI ECM Scaffolds for iPSC Islet Organoids

  2026-08-29

  Zhu and colleagues show that decellularized amniotic membrane ECM can improve the viability, maturation, function, and engraftment of iPSC-derived islet organoids. Their mechanistic analysis identifies collagen VI as a critical niche component and establishes a biomimetic scaffold strategy that more closely reproduces native islet properties.

• Dextromethorphan Hydrobromide in Neuroprotection

  2026-08-28

  Dextromethorphan hydrobromide is a research-grade NMDA receptor antagonist for dissecting excitotoxicity, ion-channel modulation, and neuroprotection. This evidence-aware guide connects assay design with lessons from modern small-molecule discovery while defining the limits of cross-domain interpretation.

• Dextromethorphan Hydrobromide: Assay Design Guide

  2026-08-28

  Dextromethorphan hydrobromide can clarify how NMDA receptor antagonism translates into measurable neuroprotection. This assay-design guide connects ion-current pharmacology, excitotoxicity models, and the orthogonal validation strategy illustrated by PDK4 inhibitor research.

• GDC-0068 (RG7440) Akt–mTOR Research Guide

  2026-08-27

  GDC-0068 (RG7440) enables dose-controlled interrogation of pan-AKT signaling in PTEN-deficient and PI3K-activated models, while its pharmacodynamic behavior helps separate Akt activity from downstream mTORC1 output. This guide combines cell-based workflow design with spatial mTORC1 concepts, assay controls, and troubleshooting strategies.

8020 records 7/535 page Previous Next First page 上5页 678910 下5页 Last page